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Objective: The relationship between diabetes and all- and cause-specific mortality
in individuals with common cancers (breast, colorectal, and prostate) remains both
under-researched and poorly understood.
Methods: Cancer survivors (N = 37,993) from the National Health Interview Survey
with linked data retrieved from the National Death Index served as our study participants.
Cox proportional-hazards models were used to assess associations between pre- and
post-diabetes and all-cause and cause-specific mortality.
Results: Over a median follow-up period of 13 years, 2,350 all-cause, 698
cancer, and 506 CVD deaths occurred. Among all cancer survivors, patients with
diabetes had greater risk of: all-cause mortality [hazard ratio (HR) 1.35, 95% CI =
1.27–1.43], cancer-specific mortality (HR: 1.14, 95% CI = 1.03–1.27), CVD mortality
(HR: 1.36, 95% CI = 1.18–1.55), diabetes related mortality (HR: 17.18, 95% CI
= 11.51–25.64), and kidney disease mortality (HR: 2.51, 95% CI = 1.65–3.82),
compared with individuals without diabetes. The risk of all-cause mortality was
also higher amongst those with diabetes and specific types of cancer: breast
cancer (HR: 1.28, 95% CI = 1.12–1.48), prostate cancer (HR: 1.20, 95% CI
= 1.03–1.39), and colorectal cancer (HR: 1.29, 95% CI = 1.10–1.50). Diabetes
increased the risk of cancer-specific mortality among colorectal cancer survivors
(HR: 1.36, 95% CI = 1.04–1.78) compared to those without diabetes. Diabetes
was associated with higher risk of diabetes-related mortality when compared to
non-diabetic breast (HR: 9.20, 95% CI = 3.60–23.53), prostate (HR: 18.36, 95% CI
= 6.01–56.11), and colorectal cancer survivors (HR: 12.18, 95% CI = 4.17–35.58).
Both pre- and post-diagnosis diabetes increased the risk of all-cause mortality among
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all cancer survivors. Cancer survivors with diabetes had similar risk of all-cause and
CVD mortality during the second 5 years of diabetes and above 10 years of diabetes
as compared to non-diabetic patients.
Conclusions: Diabetes increased the risk of all-cause mortality among breast, prostate,
and colorectal cancer survivors, not for pre- or post-diagnosis diabetes. Greater attention
on diabetes management is warranted in cancer survivors with diabetes.
Keywords: diabetes, all-cause, cancer, cardiovascular disease, mortality, cohort study
INTRODUCTION
Diabetes is a major public health burden. The prevalence of
diabetes is projected to increase to 439 million adults by 2030.
By this time, the disease burden in adults living with diabetes is
estimated to increase by 20 and 69% in developing and developed
countries, respectively (1, 2).
Diabetes mellitus (DM) and cancer are two common diseases
affecting aging populations worldwide, which commonly co-
occur. These associations are complex and may be cancer specific
(3). On one hand, strong evidence links diabetes to an increased
risk of breast and colorectal cancer onset (4, 5). On the other
hand, there is some evidence it may be associated with decreased
risk of prostate cancer onset (6). For those with a cancer diagnosis
or history of the condition, there is evidence that diabetes may
increase overall mortality risk. Previous studies have reported
that diabetes increased the all-cause and cancer-specific mortality
for cancer survivors compared to those without diabetes (7),
including breast (8), colorectal (7–9), and prostate cancer
survivors (10, 11). Interestingly, individuals with both diabetes
and a history of cancer also have higher rates of cardiovascular
mortality when compared to those without diabetes among the
general population (12, 13). However, the relationship between
diabetes and all- and cause-specific mortality in individuals with
common cancers (breast, colorectal, and prostate) remains both
under-researched and poorly understood.
This study aimed to estimate the associations of pre- and
post-diagnosis diabetes, and duration of diabetes with all-
cause, cancer-specific and CVD mortality among U.S. breast,
prostate and colorectal cancer survivors in a large prospective
cohort study.
METHODS
Study Population
The National Health Interview Survey (NHIS) is a stratified,
multistage probability survey that samples an average of 57,000
adults per year to estimate the health of the U.S. population, the
prevalence and incidence of disease, the extent of disability, and
the use of health care services. One adult is randomly selected
from each selected household for a detailed interview on health
and other behaviors.
Abbreviations: NHIS, National Health Interview Survey; DM, Diabetes mellitus;
CVD, Cardiovascular disease; CHD, Coronary heart disease; BMI, Body mass
index; MET, Metabolic equivalent task; HRs, Hazard ratios; CI, Confidence
intervals.
A total of 493,365 adults from the 13 cross-sectional waves
(i.e., from 1997 to 2013) and their linked mortality data ending in
December 31, 2015 was included in this analysis. After excluding
missing data on diabetes, we identified 37,993 adults cancer
survivors, including 6,330 breast cancer patients, 3,916 prostate
cancer patients, and 2,656 colorectal cancer patients. A total of
5,174 cancer survivors diagnosed as diabetes, including 1,020 in
breast cancer patients, 743 in prostate cancer patients and 509
in colorectal cancer patients. Totally, we identified 4,724 patients
with diabetes prior to cancer diagnosis and 450 patients with
diabetes after cancer diagnosis (Figure 1).
Diabetes
Self-reported diabetes was based on responses to questions “Have
you ever been told by a doctor or other health professional that
you had. . . ” Women reporting diabetes occurring only during
pregnancy, or adults who responded they had borderline diabetes
were considered to not have diabetes. Diabetes was dichotomized
into the presence or absence of diabetes (14, 15). Duration of
diabetes was calculated by the present age minus the age at
diagnosis of diabetes, and was categorized as <5, 5–10, and >10
years. After excluding individuals without diabetes and those
with possible type 1 diabetes adults defined by using insulin and
age of onset <30 years old which has been validated as accurate
in 97% of cases (16).
Covariables
We included demographic variables (i.e., race, gender, education,
and marital status), lifestyle variables (i.e., body mass index,
physical activity, and alcohol consumption) and comorbid
conditions [i.e., hypertension, coronary heart disease (CHD),
and stroke]. Body mass index (BMI) was calculated as weight
in kilograms divided by height squared (<25, 25–30, and >30
kg/m2). A participant’s physical activity was categorized into
three groups according tometabolic equivalent task (MET) hours
per week (low, 600 MET-h/wk; moderate, 600–3,000 MET-h/wk;
high, >3,000 MET-h/wk). Alcohol consumption was categorized
into three groups: lifetime abstainer; former drinker; current
drinker. Cancer was defined as the presence of the same National
Cancer Registry with a specific code (C code) more than three
times within a year or an in patient hospitalization with a C code
(17). Cancer diagnosed age was defined as the age at diagnosis
of cancer and was categorized into <45, 45–65, and >65 years.
Duration of cancer was calculated by the present age minus the
cancer diagnosed age.
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FIGURE 1 | Analytic sample selection.
Mortality
Ascertainment of mortality was established using the
International Classification of Diseases-10th Revision codes,
and study outcomes were defined using as follows: (1) all-
cause mortality; (2) cancer-specific mortality (i.e., codes
C00–C97); (3) CVD-mortality (i.e., codes I00–I09, I11, I13,
and I20–I51, I60–I69); (4) diabetes mellitus (E10–E14); (5)
chronic lower respiratory diseases (J40–J47); (6) influenza
and pneumonia (J09–J18); (7) Alzheimer disease (G30) and
(8) nephritis, Nephrotic syndrome and nephrosis (N00–N07,
N17–N19, N25–N27).
Statistical Analysis
We compared participants with and without diabetes for basic
characteristics using chi-square test to examine categorical
differences in the weighted percentages. According to the baseline
hazard to capture the increase in hazard due to aging, age was
used as the underlying timescale. To evaluate the association
of diabetes with all-cause, cancer and CVD mortality, we
computed multivariable-adjusted hazard ratios (HRs) and 95%
confidence intervals (CI) using cause-specific Cox proportional
hazards models. All analyses were adjusted for age (using it as a
timescale), sex, race, education level, income level, marital status,
bodymass index, smoking status, physical activity, alcohol intake,
cancer diagnosed age, duration of cancer, history of hypertension,
CHD, stroke, and missing data. We also analyzed the association
between duration of diabetes and the risk of disease-specific and
all-cause mortality. Besides, the relationship between pre- and
post-diagnosis diabetes and mortality was examined among the
5,174 men and women cancer survivors. Two sensitivity analyses
were also performed: (1) exclusion of individuals who died within
the first 2 years; (2) exclusion of participants with CHD or
stroke at interview; (3) excluding individuals with possible type 1
diabetes (defined by being on insulin and having an age of onset
<30 years).
All analyses incorporated the complex survey design and were
performed by using STATA version 15.0 (Stata Corp, College
Station, TX, USA). Two-sided p-values <0.05 were considered
significant for statistical inferences.
RESULTS
Descriptive statistics were reported in Table 1. The mean age of
cancer survivors was 63 years at baseline. Compared to cancer
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TABLE 1 | Basic characteristics.
Characteristics Subgroups Adult with diabetes (n = 5,174) Adults without diabetes (n = 29,715) P-value
N (%) N (%)
Age
18–45 years 260 (5.08%) 5,059 (16.71%) <0.001
45–65 years 1,874 (35.91%) 11,424 (39.12%)
≥65 years 3,409 (59.01%) 15,425 (44.17%)
Sex <0.001
Male 2,476 (49.13%) 12,036 (41.25%)
Female 3,067 (50.87%) 19,872 (58.75%)
Race <0.001
Hispanic 500 (6.59%) 1,851 (3.93%)
Non-Hispanic White 4,143 (81.96%) 27,006 (88.99%)
Non-Hispanic Black 764 (9.22%) 2,363 (5.07%)
Non-Hispanic Other 136 (2.23%) 688 (2.01%)
Education level <0.001
Less than high school degree 1,483 (24.10%) 5,531 (15.09%)
High school degree 1,717 (32.46%) 9,054 (28.75%)
More than high school degree 2,315 (43.44%) 17,187 (56.16%)
Income level <0.001
Low 903 (12.02%) 3,796 (8.81%)
Moderate 3,306 (59.37%) 16,748 (49.84%)
High 1,334 (28.61%) 11,364 (41.35%)
Marital status <0.001
Married/Living with partner 2,611 (61.74%) 16,273 (65.70%)
Widowed/Divorced/Separated 2,547 (32.83%) 12,804 (27.69%)
Never married 381 (5.43%) 2,791 (6.61%)
Body mass index <0.001
<25 (kg/m2 ) 1,078 (19.95%) 12,927 (41.04%)
25–30 (kg/m2) 1,827 (33.88%) 11,161 (36.53%)
>30 (kg/m2 ) 2,473 (46.17%) 6,885 (22.43%)
Physical activity <0.001
Low (<600 MET-h/wk) 4,069 (73.19%) 19,331 (60.14%)
Moderate (600–3,000 MET-h/wk) 1,100 (22.05%) 9,107 (31.41%)
High (>3,000 MET-h/wk) 237 (4.76%) 2,462 (8.45%)
Smoking status <0.001
Never smoking 2,424 (43.02%) 14,416 (45.28%)
Former smoking 2,382 (44.37%) 11,384 (36.75%)
Current smoking 700 (12.61%) 5,900 (17.96%)
Alcohol intake <0.001
Lifetime abstainer 1,450 (25.17%) 6,224 (18.09%)
Former drinker 1,945 (34.76%) 7,100 (21.63%)
Current drinker 2,066 (40.07%) 18,129 (60.27%)
Hypertension <0.001
Yes 4,243 (75.51%) 14,498 (43.49%)
No 1,297 (24.49%) 17,383 (56.51%)
Stroke <0.001
Yes 707 (12.44%) 1,849 (5.38%)
No 4,826 (87.56%) 30,014 (94.62%)
Coronary heart disease <0.001
Yes 1,270 (24.17%) 3,090 (9.52%)
No 4,241 (75.83%) 28,740 (90.48%)
Cancer diagnosed age <0.001
<45 1,295 (24.04%) 11,599 (37.79%)
45–65 2,540 (46.63%) 12,537 (40.05%)
>65 1,708 (29.33%) 7,772 (22.15%)
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TABLE 2 | Mortality of cancer survivors with pre-diagnosis diabetes group compared to non-diabetic group.
Cancer sites Mortality Deaths Adults without diabetes
(n = 29,715)
Adults with diabetes (n = 5,174)
Pre-diagnosis diabetes
(n = 4,724)
Post-diagnosis diabetes
(n = 450)
HR HR (95% CI) P-value HR (95% CI) P-value
All cancer sites
All-cause mortality 2,350 1.00 (refer) 1.35 (1.27–1.44) <0.001 1.35 (1.12–1.63) 0.002
Cancer mortality 698 1.00 (refer) 1.14 (1.02–1.28) 0.02 1.23 (0.85–1.76) 0.267
CVD mortality 506 1.00 (refer) 1.38 (1.20–1.59) <0.001 1.07 (0.67–1.70) 0.771
Chronic lower respiratory disease mortality 111 1.00 (refer) 1.12 (0.85–1.46) 0.429 1.73 (0.84–3.59) 0.138
Diabetes mellitus mortality 189 1.00 (refer) 17.82 (11.86–26.79) <0.001 8.62 (3.83–19.39) <0.001
Alzheimer’s disease mortality 42 1.00 (refer) 1.66 (1.01–2.72) 0.044 0.37 (0.09–1.60) 0.185
Influenza and pneumonia mortality 35 1.00 (refer) 0.98 (0.61–1.55) 0.917 2.18 (0.68–6.96) 0.188
Kidney disease mortality 57 1.00 (refer) 2.45 (1.60–3.75) <0.001 1.92 (0.66–5.61) 0.234
Breast (women) All-cause mortality 425 1.00 (refer) 1.31 (1.10–1.57) 0.003 1.25 (1.02–1.52) 0.03
Cancer mortality 125 1.00 (refer) NA NA NA NA
CVD mortality 79 1.00 (refer) 2.05 (0.51–8.24) 0.313 NA NA
Diabetes mellitus mortality 30 1.00 (refer) NA NA NA NA
Chronic lower respiratory disease mortality 25 1.00 (refer) NA NA 14.83 (3.67–59.88) <0.001
Alzheimer’s disease mortality 11 1.00 (refer) NA NA NA NA
Influenza and pneumonia mortality 8 1.00 (refer) NA NA NA NA
Kidney disease mortality 11 1.00 (refer) 79.35 (4.93–1,277.73) 0.002 NA NA
Prostate All-cause mortality 333 1.00 (refer) 1.21 (1.01–1.43) 0.036 1.18 (0.93–1.51) 0.18
Cancer mortality 103 1.00 (refer) 1.38 (0.38–4.98) 0.621 0.69 (0.07–6.71) 0.75
CVD mortality 78 1.00 (refer) NA NA NA NA
Diabetes mellitus mortality 21 1.00 (refer) NA NA NA NA
Chronic lower respiratory disease mortality 15 1.00 (refer) 3.62 (1.12–11.72) 0.032 NA NA
Alzheimer’s disease mortality 4 1.00 (refer) 16.44 (1.86–145.26) 0.012 NA NA
Influenza and pneumonia mortality 5 1.00 (refer) NA NA NA NA
Kidney disease mortality 4 1.00 (refer) NA NA NA NA
Colorectal All-cause mortality 272 1.00 (refer) 1.19 (0.77–1.84) 0.441 0.98 (0.33–2.93) 0.969
Cancer mortality 96 1.00 (refer) 1.89 (0.51–7.02) 0.34 NA NA
CVD mortality 57 1.00 (refer) NA NA NA NA
Diabetes mellitus mortality 24 1.00 (refer) NA NA NA NA
Chronic lower respiratory disease mortality 8 1.00 (refer) NA NA NA NA
Alzheimer’s disease mortality 4 1.00 (refer) NA NA NA NA
Influenza and pneumonia mortality 1 1.00 (refer) NA NA NA NA
Kidney disease mortality 5 1.00 (refer) NA NA NA NA
CVD, cardiovascular disease; HR, hazard ratios.
Adjusted for age, sex, race, education level, income level, marital status, body mass index, smoking status, alcohol intake, physical activity, cancer diagnosed age, duration of cancer,
history of hypertension, coronary heart disease and stroke, and missing data.
survivors without diabetes, cancer survivors with diabetes were
more likely to be obesity (i.e., BMI > 30 kg/m2) and be less
physically active (i.e., low physical activity). Cancer survivors
with diabetes tend to have a degree less than high school (24.1%
in patients with diabetes, 15.09% in patients without diabetes).
Patients with diabetes tend to have a history of hypertension
(75.51% in patients with diabetes, 43.49% in patients without
diabetes), CHD (24.17% in patients with diabetes, 9.52% in
patients without diabetes), and stroke (12.44% in patients with
diabetes, 5.38% in patients without diabetes).
After a median follow-up period of 13 years, 2,346 all-
cause, 698 cancer-specific, and 506 CVD deaths occurred.
Figure 2 showed the risk of all-cause, cancer and CVD
mortality among diabetic cancer survivors compared to non-
diabetic cancer survivors. Compared to non-diabetes cancer
survivors, cancer survivors with diabetes had a 35% higher
risk of all-cause mortality (HR: 1.35, 95% CI = 1.27–
1.43), 14% higher risk of cancer mortality (HR: 1.14, 95%
CI = 1.03–1.27), and 36% higher risk of CVD mortality
(HR: 1.36, 95% CI = 1.18–1.55). These relationships were
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FIGURE 2 | Mortality of cancer survivors with diabetes compared to non-diabetic cancer survivors (adjusted for age, sex, race, education level, income level, marital
status, body mass index, smoking status, alcohol intake, physical activity, cancer diagnosed age, duration of cancer, history of hypertension, coronary heart disease
and stroke, and missing data).
stronger for diabetes related mortality (HR: 17.18, 95%
CI = 11.51–25.64) and kidney disease mortality 2.51 for
(95% CI = 1.65–3.82) who were diabetic survivors when
compared to non-diabetic survivors, but no associations
were observed between diabetes and risk of chronic lower
respiratory disease, influenza and pneumonia, and Alzheimer
disease mortality.
The HRs for all-cause mortality varied from 1.20 to 1.30
among survivors with diabetes diagnosed with breast cancer (HR:
1.28, 95% CI = 1.12–1.48), prostate cancer (HR: 1.20, 95% CI =
1.03–1.39), and colorectal cancer (HR = 1.29, 95% CI = 1.10–
1.50). Diabetes increased the risk of cancer-specific mortality
among colorectal cancer survivors (HR: 1.36, 95% CI = 1.04–
1.78) compared to non-diabetic survivors, but not in breast and
prostate cancer survivors. Diabetes was associated with higher
risk of diabetes related mortality in breast (HR: 9.20, 95% CI
= 3.60–23.53), prostate (HR: 18.36, 95% CI = 6.01–56.11), and
colorectal cancer survivors (HR: 12.18, 95% CI = 4.17–35.58),
compared to non-diabetic cancer survivors. Diabetes increased
the risk of chronic lower respiratory disease mortality (HR:
1.92, 95% CI = 1.14–3.24) and kidney disease mortality (HR:
2.96, 95% CI = 1.07–8.22) among breast survivors compared
to non-diabetic survivors, but not in colorectal and prostate
cancer survivors.
Pre-diagnosis diabetes increased the risk of all-cause mortality
(HR: 1.35, 95% CI= 1.27–1.44), cancer mortality (HR: 1.14, 95%
CI= 1.02–1.28), CVDmortality (HR: 1.38, 95% CI= 1.20–1.59),
diabetes mellitus mortality (HR: 17.82, 95% CI = 11.86–26.79),
Alzheimer’s disease mortality (HR: 1.66, 95% CI = 1.01–2.72),
and kidney disease mortality (HR: 2.45, 95% CI = 1.60–3.75),
respectively among all cancer survivors. Post-diagnosis diabetes
increased the risk of all-cause mortality (HR: 1.35, 95% CI =
1.12–1.63) and diabetes mellitus mortality (HR: 8.62, 95% CI =
3.83–19.39), but not in other mortality. For specific cancer sites,
pre-diagnosis diabetes increased the risk of all-cause mortality
in prostate (HR: 1.21, 95% CI = 1.01–1.43) and breast cancer
survivors (HR: 1.31, 95% CI = 1.10–1.57), not in colorectal
cancer survivors. Post-diagnosis diabetes did not confer obvious
increased risk of all-cause mortality for prostate and colorectal
cancer sites except breast cancer (HR: 1.25, 95% CI= 1.02–1.52).
Additional information were detailed in Table 2.
As summarized in Table 3, cancer survivors with diabetes had
similar risk of all-cause and CVD mortality during the second
5 years of diabetes [(HR: 1.44, 95% CI = 1.29–1.60); (HR: 1.43,
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TABLE 3 | Duration of diabetes among cancer survivors compared to those without diabetes.
Cancer sites Mortality Adults without
diabetes
Adults with diabetes
0–5 years 5–10 years >10 years
HR HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
All cancer sites
All-cause mortality 1.00 (refer.) 1.21 (1.09, 1.33) <0.001 1.44 (1.29–1.60) <0.001 1.41 (1.30–1.52) <0.001
Cancer mortality 1.00 (refer.) 1.13 (0.97, 1.33) 0.123 1.40 (1.15–1.70) 0.001 1.04 (0.89–1.21) 0.624
CVD mortality 1.00 (refer.) 1.14 (0.91, 1.43) 0.261 1.43 (1.13–1.82) 0.004 1.45 (1.22–1.71) <0.001
Chronic lower respiratory disease mortality 1.00 (refer.) 1.21 (1.10, 1.34) <0.001 1.44 (1.29–1.60) <0.001 1.41 (1.31–1.53) <0.001
Alzheimer’s disease mortality 1.00 (refer.) 0.67 (0.26, 1.74) 0.408 2.20 (1.09–4.42) 0.027 1.71 (0.91–3.23) 0.098
Diabetes mellitus mortality 1.00 (refer.) 10.97 (6.28, 19.16) <0.001 11.04 (6.20–19.64) <0.001 24.11
(15.55–37.38)
<0.001
Influenza and pneumonia mortality 1.00 (refer.) 0.97 (0.43, 2.21) 0.95 0.55 (0.20–1.55) 0.258 1.29 (0.76–2.20) 0.342
Kidney disease mortality 1.00 (refer.) 1.83 (0.84, 3.98) 0.129 4.29 (2.02–9.12) <0.001 2.25 (1.35–3.73) 0.002
Breast (women)
All-cause mortality 1.00 (refer.) 1.22 (0.94, 1.56) 0.13 1.13 (0.88–1.46) 0.328 1.38 (1.16–1.64) <0.001
Cancer mortality 1.00 (refer.) 0.96 (0.62, 1.47) 0.849 1.26 (0.82–1.94) 0.283 0.89 (0.64–1.26) 0.521
CVD mortality 1.00 (refer.) 1.18 (0.64, 2.18) 0.588 0.87 (0.41–1.87) 0.727 1.31 (0.87–1.99) 0.2
Chronic lower respiratory disease mortality 1.00 (refer.) 1.22 (0.95, 1.57) 0.125 1.14 (0.88–1.47) 0.311 1.37 (1.15–1.63) <0.001
Alzheimer’s disease mortality 1.00 (refer.) 0.16 (0.02, 1.21) 0.076 0.51 (0.06–4.14) 0.526 2.35 (0.73–7.56) 0.153
Diabetes mellitus mortality 1.00 (refer.) 4.92 (1.42, 16.99) 0.012 5.61 (1.45–21.68) 0.013 13.45 (4.77–37.97) <0.001
Influenza and pneumonia mortality 1.00 (refer.) 1.63 (0.35, 7.53) 0.529 1.65 (0.38–7.07) 0.501 0.53 (0.11–2.48) 0.414
Kidney disease mortality 1.00 (refer.) 0.66 (0.07, 6.62) 0.72 NA NA 5.41 (1.84–15.87) 0.002
Prostate
All-cause mortality 1.00 (refer.) 1.11 (0.86, 1.42) 0.424 1.42 (1.07–1.89) 0.015 1.17 (0.96–1.41) 0.118
Cancer mortality 1.00 (refer.) 1.31 (0.90, 1.91) 0.156 1.28 (0.74–2.20) 0.381 0.92 (0.65–1.31) 0.644
CVD mortality 1.00 (refer.) 1.05 (0.58, 1.92) 0.871 1.51 (0.81–2.83) 0.194 1.12 (0.74–1.71) 0.592
Chronic lower respiratory disease mortality 1.00 (refer.) 1.11 (0.86, 1.43) 0.41 1.43 (1.08–1.90) 0.014 1.17 (0.97–1.42) 0.107
Alzheimer’s disease mortality 1.00 (refer.) 0.96 (0.12, 7.74) 0.972 NA NA 1.89 (0.42–8.56) 0.405
Diabetes mellitus mortality 1.00 (refer.) 10.18 (2.16, 48.02) 0.003 16.29 (3.29–80.75) 0.001 25.25 (7.85–81.25) <0.001
Influenza and pneumonia mortality 1.00 (refer.) 0.21 (0.03, 1.57) 0.127 0.72 (0.09–5.91) 0.757 0.31 (0.05–1.73) 0.179
Kidney disease mortality 1.00 (refer.) 2.72 (0.47, 15.59) 0.261 5.60 (2.41–13.03) <0.001 0.60 (0.06–5.83) 0.661
Colorectal
All-cause mortality 1.00 (refer.) 1.19 (0.90, 1.58) 0.219 1.34 (0.98–1.82) 0.064 1.32 (1.08–1.60) 0.006
Cancer mortality 1.00 (refer.) 1.29 (0.85, 1.98) 0.236 1.57 (0.91–2.72) 0.106 1.31 (0.90–1.89) 0.154
CVD mortality 1.00 (refer.) 1.13 (0.55, 2.29) 0.743 0.98 (0.46–2.09) 0.956 1.42 (0.88–2.29) 0.149
Chronic lower respiratory disease mortality 1.00 (refer.) 1.20 (0.91, 1.59) 0.198 1.34 (0.99–1.83) 0.059 1.33 (1.09–1.62) 0.005
Alzheimer’s disease mortality 1.00 (refer.) 1.21 (0.10, 14.85) 0.881 2.91 (0.54–15.76) 0.215 0.47 (0.06–3.82) 0.476
Diabetes mellitus mortality 1.00 (refer.) 0.71 (0.08, 6.33) 0.756 5.54 (1.10–27.86) 0.038 23.47 (7.43–74.17) <0.001
Influenza and pneumonia mortality 1.00 (refer.) NA NA NA NA 0.49 (0.08–3.09) 0.444
Kidney disease mortality 1.00 (refer.) 0.98 (0.10, 9.18) 0.985 0.99 (0.19–5.11) 0.994 0.73 (0.22–2.43) 0.604
CVD, cardiovascular disease; HR, hazard ratios.
Adjusted for age, sex, race, education level, income level, marital status, body mass index, smoking status, alcohol intake, physical activity, cancer diagnosed age, duration of cancer,
history of hypertension, coronary heart disease and stroke, and missing data.
95% CI= 1.13–1.82)] and above 10 years [(HR= 1.41, 95% CI=
1.30–1.52); (HR: 1.45, 95% CI= 1.22–1.71)] as compared to non-
diabetic participants. However, cancer survivors with duration of
diabetes 5–10 years (HR: 1.40, 95% CI= 1.15–1.70) achieved the
highest risk of cancer mortality compared to those with duration
of diabetes <5 years or more than 10 years. Compared to non-
diabetic survivors, cancer survivors with diabetes with duration
for 0–5 years (HR: 10.97, 95% CI = 6.28–19.16), 5–10 years
(HR: 11.04, 95% CI = 6.20–19.64), and more than 10 years (HR:
24.11, 95% CI = 15.55–37.38) were at increased risk of diabetes
related mortality.
We conducted a sensitivity analysis excluding individuals who
were followed up for less than the first 2 years, those with CHD,
stroke. Exclusion of individuals with possible type 1 diabetes did
not largely affect the HRs indicating the robustness of results
(data not shown).
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DISCUSSION
This large prospective study showed that compared to cancer
survivors without diabetes, cancer survivors with diabetes had
higher risk of all-cause, cancer-specific, and CVD mortality.
Further they had an increased risk of all-cause, but not
cancer specific mortality as the duration of diabetes increased.
These findings add to a largely equivocal evidence base on
this relationship.
Diabetes elevates all-cause and cancer specific mortality is
consistent with a recent study which showed similar findings in
individuals with established prostate cancer (11) as well as other
studies in patients with breast and colorectal cancer (8). Some
types of cancer are treated less aggressively in cancer survivors
with diabetes than those without diabetes (18). In our study, pre-
diagnosis diabetes increased the risk of all-cause mortality after
adjusting for covariables in breast and prostate cancer sites, which
is not consistent with previous findings (19, 20). But additional
evidence indicated that pre-existing diabetes increased the risk
of all-cause mortality among women with breast cancer after
adjusting for covariables related to delayed diagnosis and therapy
(21). In addition, pre-diagnosis diabetes increased the risk of all-
cause mortality in colorectal cancer survivors in our study, which
is consistent with findings in previous study (20).
Our second finding, that all-cause (but not cancer specific)
mortality risk increased with diabetes duration has been observed
previously in those with colorectal and breast cancer, respectively.
With respect to the former group, diabetes duration of more
than 10 years was associated with a 49% higher risk of all-cause
mortality (22), which is slightly greater than the magnitude of
association we observed (33%). With respect to the latter group,
we found the risk of all-cause mortality increased in breast cancer
patients who have had diabetes for more than 10 years, while
others have shown increased risk from 7 years (23).
Among non-diabetic patients, hyperinsulinemia associated
with reduced insulin sensitivity may play a role in the
pathogenesis of prostate carcinoma (24). Thus, our study might
underestimate the effect between insulin secretion or increase of
insulin resistance and mortality among cancer survivors. Cancer
survivor with diabetes have the same CVD risk of mortality
during the second 5 years of diabetes and above 10 years as
compared to non-diabetic patients. But this is not aspected since
type 2 diabetes abnormalities (such as reduced insulin secretion,
increase of insulin resistance) start several years before that the
diabetes clinical manifestations appears.
Previous studies indicated the possible relationship between
diabetic status and less aggressive oncological treatment and
worse overall survival (18). In our study, all-cause mortality
(but not cancer-specific) increase in long-standing diabetes
diagnosis (>10 years) is likely to be related with the increase of
potentially fatal events related to diabetic complications partially
explaining the reduced cancer-mortality observed in this group
in comparison with the 5–10 years group. A slight increase
cancer-related mortality in recently diagnosed diabetic patient
(0–5 years group) is likely to be related with short-time exposure
to the risk of development of diabetes complications able to
influence the oncological treatment strategies.
Diabetes could increase the risk of all-cause mortality among
population with different diseases. In our study, both pre- and
post-diagnosis diabetes increased the risk of all-cause mortality
by 35% than non-diabetic cancer survivors, which was higher
than that with 23% among tuberculosis patients (25). Previous
studies indicated that patients with diabetes who underwent
incident amputation have a 55% higher risk for all-cause
mortality than non-diabetic patients (26), and diabetes increased
the total mortality markedly with a higher 70% among patients
hospitalized with a confirmed acute myocardial infarction than
non-diabetic patients (27). In addition, individuals with vs.
those without diabetes were at increased higher risk of all-cause
mortality in the earlier (144%) and later time (95%) periods in the
Framingham Heart Study (28).
There are several mechanistic pathways by which diabetes
may confer elevated mortality risk in individuals with cancer
history. Cancer patients with diabetes often have other
diabetes-related comorbid conditions, which may influence
physicians’ clinical decision making (29). For example, cancer
survivors with diabetes have been shown to be treated less
aggressively with chemotherapy and radiotherapy (18, 30).
This could partially explain the worse prognosis compared
to those without diabetes. Secondly, individuals with co-
morbid cancer and diabetes may have poor response to
cancer treatment, including increased infection rates and
intraoperative mortality (31). Thirdly, they may have a
greater risk of chemotherapy-related toxicity (i.e., dilated
cardiomyopathy in breast cancer) (30). Thus, conservative
clinical decision making or side effects of conventional cancer
treatments may impair survival time for individuals with
this comorbidity.
The presence of diabetes may itself influence cancer
progression via physiologic processes of hyperinsulinemia,
hyperglycemia, immunodeficiency, and chronic inflammation.
It is possible that most glucose uptake in cancer cells is
constitutively high and independent of insulin binding to
insulin-like growth factor receptor, which could stimulate cancer
cell proliferation and metastasis (32, 33). Another potential
pathway is that acute exposure to hyperglycemia may increase
endothelial cell permeability for reasons of increased generation
of reactive oxidative species and structural changes in the
basement membrane, increasing the probability of metastasis
(34). The third possible pathway is that hyperinsulinemia related
to underlying insulin resistance might stimulate tumor growth
(35). Multiple downstream signaling pathways are activated after
insulin receptors interact with their ligands, and can stimulate
multiple cancer phenotypes contribute to tumor initiation and
progression (36). Decreased immunity induced by diabetes can
also lead to cancer progression. In this study, the risk of diabetes
related mortality increased obviously among cancer survivors
with diabetes when compared to non-diabetic survivors. The
increased mortality can be reversed when diabetes is managed
well in clinical practice.
Limitations
Our study has several strengths including the large, prospective
nature of the cohort used. The representativeness of the sample
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further adds to the robustness of the findings. Nonetheless, our
study had certain limitations. Firstly, we used an epidemiological
definition of type 1 diabetes, which implies that misclassification
of diabetes type is possible. However, a validation study has
shown that those with possible type 1 diabetes adults defined
by using insulin and age of onset <30 years old which has
been validated as accurate in 97% of cases (16). This could be
a potential bias for patients selection in our study. Secondly,
we did not have extensive clinical parameters regarding disease
status for diabetes and its comorbidities and cancer. For
instance, insulin therapy has been associated with increased
risk of newly developed colorectal cancer (37), however we
could not account for this in the model. Thirdly, lacking of
informations about pharmacological and/or surgical treatment
received for either diabetes or cancer fail to identify subgroups
of cancer survivors who may have been at risk of high mortality
rate because of the cancer treatment they received. Fourthly,
although diabetes assessments were from self-reports, it is
always possible to include the participants who had never
received the appropriate diagnostic tests of diabetes, and to
misclassify the diabetes as non-diabetes. Self-report of cancer
duration or diabetes implies high probability of incorrect
data assumed as correct. Finally, our findings may not be
generalizable to other cancer sites except for breast, colorectal,
and prostate cancer.
CONCLUSION
Breast, prostate, and colorectal cancer survivors with diabetes
had higher risk of all-cause mortality than did cancer survivors
without diabetes. Pre-diagnosis diabetes increased risk of all-
cause mortality after adjusting for covariables in breast and
prostate cancer sites. Duration of diabetes is associated with
increased risk of all-cause but not cancer specific mortality when
compared to non-diabetic breast and prostate cancer survivors.
Greater attention on diabetes control might be warranted in those
with comorbid cancer and diabetes.
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